David Reese (file photo)
June 1, 2021 04:03 AM EDTUpdated June 3, 11:34 AM
Deals

Am­gen beefs up its late-stage pipeline with a $400M cash deal to go up against heavy­weight ri­vals in a PhI­II atopic der­mati­tis show­down

John Carroll

Editor & Founder

Three months af­ter Ky­owa Kirin claimed a hit for their mid-stage pro­gram test­ing the an­ti-OX40 an­ti­body KHK4083 for mod­er­ate to se­vere atopic der­mati­tis, Am­gen is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times